[29-413-pm] Structure-activity relationship/Middle-molecule drugs/Screening

Fri. Mar 29, 2024 3:30 PM - 4:30 PM [Room 413] Conference Center 413 (4F)

Chair: Taketo Uchiyama, Akio Ojida

+Add all to schedule

3:30 PM - 3:42 PM

[29-413-pm11S] Efficient structural development of hydrophobic moiety in progesterone receptor (PR) ligands using hydroboration of vinylsilanes

○Nao Namba¹, Hiroyuki Kagechika¹, Shinya Fujii¹ (1. Institute of Biomedical and Bioengineering, Tokyo Medical and Dental University)

3:42 PM - 3:54 PM

[29-413-pm12S] Identifying the absolute configuration of the most potent isomer of tryptolinamide as a phosphofructokinase-1 inhibitor

○Ryo Kakehi¹, Hiroki Kobayashi^2,3, Haruna Nishimura², Tatsuo Yajima¹, Minoru Yoshida^2,4, Yasuo Nagaoka¹, Takaaki Sumiyoshi¹ (1. Dept. Life Sci. & Tech., Kansai Univ., 2. RIKEN CSRS, 3. Tokyo Univ. Pharm. Life Sci., 4. Dept. Biotechnol., Univ. Tokyo.)

3:54 PM - 4:06 PM

[29-413-pm13] Creation of antiviral G quadruplex RNA oligomers

○Shusuke Kuge¹ (1. Faculty of Pharm. Sci., Tohoku Med. Pharm. Univ.)

4:06 PM - 4:18 PM

[29-413-pm14S] Development of peptide-PROTACs based on stapling by an E3 ligand

○Hiroaki Kawanami¹, Yuri Takada¹, Yasunobu Yamashita¹, Yukihiro Itoh¹, Takayoshi Suzuki¹ (1. SANKEN, Osaka Univ.)

4:18 PM - 4:30 PM

[29-413-pm15S] Discovery study on CBX7 inhibitors based on peptide library construction and screening

○Ibuki Yamazaki¹, Yuri Takada¹, Yasunobu Yamashita¹, Yukihiro Itoh¹, Takayoshi Suzuki¹ (1. SANKEN, Osaka University)

Session information